Brief: AIM Vaccine Says Bivalent Mrna Vaccine Against Covid-19 Variants Obtained Clinical Trial Approvals
29/06/2023 24:56
June 29 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* BIVALENT MRNA VACCINE AGAINST COVID-19 VARIANTS DELTA AND
OMICRON BA.5 OBTAINED CLINICAL TRIAL APPROVALS
* BIVALENT MRNA VACCINE AGAINST COVID-19 VARIANTS OBTAINED
CLINICAL TRIAL APPROVALS FROM NMPA OF CHINA
Source text for Eikon: ID:
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine